ZURICH (Reuters)-an experimental skin cancer drug Roche vismodegib was given the status of "priority review" by the US Government, Switzerland drugmaker said on Wednesday. "
The news comes hot on the heels of an agreement in August for Roche's targeted drug Zelboraf to turn off form of skin cancer, which came two months off schedule.
Food and Drug Administration now will consider the use of vismodegib, another targeted drugs, to treat adults with advanced basal cell carcinoma is the most common types of skin cancer-for whom surgery is not thought to be an option.
The FDA says that the time it takes to review new drug applications reduced to review priorities, with the goal to complete a six-month period.
Vismodegib, a type of medicine called Hedgehog pathway inhibitor, show the results of the "extraordinary" in the mid-stage, be substantially shrinking tumors and lesions in patients with fatal kind of skin cancer.